|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.20 CNY | -1.23% |
|
-0.14% | -5.69% |
| 11:55am | Gan & Lee Pharmaceuticals 2025 net profit up 86.1% y/y | RE |
| 04-16 | Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1062 Injection | MT |
| Capitalization | 39.09B 5.73B 4.88B 4.47B 4.24B 7.82B 536B 8B 52.52B 20.67B 257B 21.5B 21.06B 914B | P/E ratio 2025 * |
34.3x | P/E ratio 2026 * | 26.6x |
|---|---|---|---|---|---|
| Enterprise value | 37.74B 5.53B 4.71B 4.32B 4.1B 7.55B 518B 7.72B 50.7B 19.95B 248B 20.75B 20.32B 882B | EV / Sales 2025 * |
9.09x | EV / Sales 2026 * | 7.07x |
| Free-Float |
50.32% | Yield 2025 * |
0.28% | Yield 2026 * | 0.37% |
| 1 day | -1.23% | ||
| 1 week | -0.14% | ||
| Current month | +0.31% | ||
| 1 month | +7.63% | ||
| 3 months | -10.56% | ||
| 6 months | -9.44% | ||
| Current year | -5.69% |
| 1 week | 63.89 |  | 66.44 |
| 1 month | 55.8 | | 66.57 |
| Current year | 55.8 | | 74.47 |
| 1 year | 44.68 | | 82.25 |
| 3 years | 32.1 | | 82.25 |
| 5 years | 30.53 | | 138.5 |
| 10 years | 30.53 | | 204.41 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Chen
CEO | Chief Executive Officer | 46 | - |
Qi Wang
DFI | Director of Finance/CFO | - | 08/03/2026 |
Ting Jia
CTO | Chief Tech/Sci/R&D Officer | - | 08/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Zhong Ru Gan
CHM | Chairman | 78 | 16/06/1998 |
Kai Du
BRD | Director/Board Member | 49 | 31/12/2009 |
Wei Qiang Song
BRD | Director/Board Member | 44 | 14/09/2015 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.23% | -0.14% | +45.94% | +78.48% | 5.6B | |
| +0.43% | -0.05% | +28.71% | -5.45% | 76.69B | |
| -2.59% | -9.22% | +72.04% | +174.53% | 55.29B | |
| -1.06% | +58.80% | +58.80% | +58.80% | 49.73B | |
| -5.70% | -7.35% | -45.39% | -57.55% | 47.08B | |
| +2.56% | +6.20% | +61.27% | -34.57% | 27.29B | |
| +1.19% | +1.58% | +114.14% | -60.10% | 21.51B | |
| +1.20% | +0.75% | +70.49% | +30.01% | 19.15B | |
| -0.92% | -0.73% | +54.11% | +55.04% | 15.53B | |
| -2.99% | -4.74% | +116.56% | +386.65% | 14.77B | |
| Average | -0.80% | -0.81% | +57.67% | +62.58% | 33.26B | |
| Weighted average by Cap. | -1.01% | -1.49% | +45.90% | +44.46% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 4.15B 608M 518M 475M 450M 831M 56.92B 849M 5.58B 2.19B 27.31B 2.28B 2.24B 97B | 5.24B 769M 654M 600M 569M 1.05B 71.91B 1.07B 7.04B 2.77B 34.51B 2.88B 2.82B 123B |
| Net income | 1.12B 165M 140M 129M 122M 225M 15.42B 230M 1.51B 594M 7.4B 618M 605M 26.27B | 1.45B 213M 181M 166M 157M 290M 19.89B 297M 1.95B 767M 9.54B 797M 781M 33.89B |
| Net Debt | -1.36B -199M -169M -155M -147M -271M -18.6B -277M -1.82B -717M -8.92B -746M -730M -31.69B | -2.02B -295M -251M -231M -219M -403M -27.64B -412M -2.71B -1.07B -13.26B -1.11B -1.09B -47.1B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/04/26 | 65.68 ¥ | +2.31% | 6,956,055 |
| 21/04/26 | 64.20 ¥ | -1.23% | 4,538,311 |
| 20/04/26 | 65.00 ¥ | -0.23% | 3,973,985 |
| 17/04/26 | 65.15 ¥ | -1.24% | 5,611,489 |
| 16/04/26 | 65.97 ¥ | +0.02% | 6,239,058 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 603087 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition